Locoregional Tumor Burden and Risk of Mortality in Metastatic Breast Cancer

Overview

Journal NPJ Precis Oncol

Publisher Springer Nature

Specialty Oncology

Date 2022 Apr 6

PMID 35383277

Authors

Sherry X Yang

Stephen M Hewitt

John Yu

Affiliations

Soon will be listed here.

Abstract

The role of lymph node involvement and tumor size in metastatic disease including breast cancer is unclear. Here, nodal metastasis and T stage on the risk of mortality were investigated in de novo metastatic breast cancer population (35812 patients) in the Surveillance, Epidemiology, and End Results (SEER) Program database in the United States. We found an association between all-cause mortality and regional node involvement (adjusted hazard ratio [HR] = 1.45, 95% confidence interval [CI] 1.36-1.55, p < 0.0001) or T stage (HR = 1.20, 95% CI 1.14-1.25, p < 0.0001), independent of known clinicopathologic measurements. Number of positive nodes, and size and chest wall involvement of the breast tumors exhibited similar significance for breast cancer-specific mortality in the population (p < 0.0001 each), and all-cause mortality in hormone receptor (HR)-positive/HER2-negative (HR/HER2), HR/HER2, HR/HER2 and triple-negative metastatic breast cancer subtypes. Thus, nodal involvement and T stage are independent risk factors for mortality in the population of de novo metastatic breast cancer.

Citing Articles

Elacestrant plus alpelisib in an and co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety.

Tokat U, Bilgic S, Aydin E, Adibi A, Ozgu E, Tutar O Ther Adv Med Oncol. 2024; 16:17588359241297101.

PMID: 39539943 PMC: 11558728. DOI: 10.1177/17588359241297101.

Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy.

Ji L, Song G, Xiao M, Chen X, Li Q, Wang J Thorac Cancer. 2024; 15(30):2193-2205.

PMID: 39279162 PMC: 11496194. DOI: 10.1111/1759-7714.15452.

Dessie Z, Zewotir T Front Public Health. 2024; 12():1356430.

PMID: 39109161 PMC: 11300231. DOI: 10.3389/fpubh.2024.1356430.

Patterns of metastasis and survival outcomes by age in breast cancer patients: a SEER population-based study.

Xiao Q, Zhang W, Jing J, Zhong T, Li D, Zhou J Front Endocrinol (Lausanne). 2023; 14:1184895.

PMID: 38027167 PMC: 10657995. DOI: 10.3389/fendo.2023.1184895.

Single-Cell Transcriptomic Profiles of Lung Pre-Metastatic Niche Reveal Neutrophil and Lymphatic Endothelial Cell Roles in Breast Cancer.

Huang Y, Chang C, Wu Y, Wu K, Tsai Y, Lee H Cancers (Basel). 2023; 15(1).

PMID: 36612175 PMC: 9818165. DOI: 10.3390/cancers15010176.

References

Carter C, Allen C, Henson D . Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63(1):181-7. DOI: 10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h. View

Hortobagyi G, Smith T, Legha S, Swenerton K, Gehan E, Yap H . Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983; 1(12):776-86. DOI: 10.1200/JCO.1983.1.12.776. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Prat A, Cheang M, Galvan P, Nuciforo P, Pare L, Adamo B . Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncol. 2016; 2(10):1287-1294. DOI: 10.1001/jamaoncol.2016.0922. View

DeSantis C, Ma J, Gaudet M, Newman L, Miller K, Sauer A . Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6):438-451. DOI: 10.3322/caac.21583. View

Elkin E, Hudis C, Begg C, Schrag D . The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer. 2005; 104(6):1149-57. DOI: 10.1002/cncr.21285. View

Baselga J, Cortes J, Kim S, Im S, Hegg R, Im Y . Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2011; 366(2):109-19. PMC: 5705202. DOI: 10.1056/NEJMoa1113216. View

Yang S, Polley E, Nguyen D . Association of γH2AX at Diagnosis with Chemotherapy Outcome in Patients with Breast Cancer. Theranostics. 2017; 7(4):945-951. PMC: 5381256. DOI: 10.7150/thno.19102. View

Foulkes W, Reis-Filho J, Narod S . Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol. 2010; 7(6):348-53. DOI: 10.1038/nrclinonc.2010.39. View

10.

Bitencourt A, Rossi Saccarelli C, Morris E, Flynn J, Zhang Z, Khan A . Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer. JAMA Netw Open. 2020; 3(10):e2018790. PMC: 7547365. DOI: 10.1001/jamanetworkopen.2020.18790. View

11.

Moy B, Rumble R, Come S, Davidson N, Di Leo A, Gralow J . Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021; 39(35):3938-3958. DOI: 10.1200/JCO.21.01374. View

12.

Andreopoulou E, Hortobagyi G . Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol. 2008; 26(22):3660-2. DOI: 10.1200/JCO.2008.16.1026. View

13.

Seoane J, Kirkland J, Caswell-Jin J, Crabtree G, Curtis C . Chromatin regulators mediate anthracycline sensitivity in breast cancer. Nat Med. 2019; 25(11):1721-1727. PMC: 7220800. DOI: 10.1038/s41591-019-0638-5. View

14.

Hortobagyi G . Treatment of breast cancer. N Engl J Med. 1998; 339(14):974-84. DOI: 10.1056/NEJM199810013391407. View

15.

Dawood S, Broglio K, Ensor J, Hortobagyi G, Giordano S . Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010; 21(11):2169-2174. PMC: 2962259. DOI: 10.1093/annonc/mdq220. View

16.

Yang S, Polley E . Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up. Breast Cancer Res Treat. 2019; 175(2):287-295. PMC: 6533413. DOI: 10.1007/s10549-019-05142-x. View

17.

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Yang S, Costantino J, Kim C, Mamounas E, Nguyen D, Jeong J . Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol. 2010; 28(18):2974-81. PMC: 2903333. DOI: 10.1200/JCO.2009.26.1602. View

20.

Mariotto A, Noone A, Howlader N, Cho H, Keel G, Garshell J . Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014; 2014(49):145-86. PMC: 4829054. DOI: 10.1093/jncimonographs/lgu024. View